What Catalysts Are Rewriting The Story For Agios Pharmaceuticals (AGIO)? [Yahoo! Finance]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Yahoo! Finance
the same 7.05%. That move reflects updated revenue growth assumptions of 115.05%, up from 111.60%. This change ties directly to how analysts are weighing the potential of Pyrukynd in thalassemia and the longer term optionality around mitapivat in sickle cell disease, despite the mixed RISE UP readout. As you read on, you will see how these shifting expectations are feeding into the story around Agios and how you can keep on top of future changes in the narrative. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Agios Pharmaceuticals. ?? Bullish Takeaways BofA and Citi sit on the optimistic side, each with Buy ratings and price targets in the low to high US$30s, framing Agios as one of the biopharma names they see benefiting from improving sector sentiment and M&A interest. Citi highlights Pyrukynd in thalassemia as a key driver, pointing to Phase 3 data it views as supportive of approval and flagging the earli
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio GrowthGlobeNewswire
- Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by analysts at JPMorgan Chase & Co. from $20.00 to $25.00. They now have a "neutral" rating on the stock.MarketBeat
- Compass Therapeutics Announces Key Leadership Appointments [Yahoo! Finance]Yahoo! Finance
- Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026GlobeNewswire
- Agios Pharmaceuticals (NASDAQ:AGIO) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
AGIO
Earnings
- 10/30/25 - Beat
AGIO
Sec Filings
- 1/12/26 - Form 8-K
- 1/7/26 - Form 4
- 1/5/26 - Form 144
- AGIO's page on the SEC website